Pedersen A W, Holmstrøm K, Jensen S S, Fuchs D, Rasmussen S, Kvistborg P, Claesson M H, Zocca M-B
DanDrit Biotech A/S, Copenhagen, Denmark.
Clin Exp Immunol. 2009 Jul;157(1):48-59. doi: 10.1111/j.1365-2249.2009.03961.x.
The clinical use of dendritic cells (DCs) to induce antigen-specific immune tolerance has been hampered by the lack of a widely acknowledged method for generating human regulatory DCs but even more so by the non-existence of reliable markers. Thus, we set out to find reliable markers that can be measured with simple methods to identify regulatory DCs that are applicable for future clinical studies. Human DCs were generated from peripheral blood monocytes in the presence of 1alpha,25-dihydroxyvitamin D(3) (VD3), which gave rise to a phenotype that resembles immature DCs, with the exception of high CD14 and reduced CD1a on the cell surface. These VD3-treated DCs exert a long-lasting inefficient T cell stimulation and induce T cell hyporesponsiveness with regulatory potential. Importantly, such VD3-treated DCs were readily distinguishable from untreated DCs by low levels of interleukin-23 secretion and low expression of miR-155 upon exposure to maturation stimuli. Furthermore, VD3-treated DCs showed over-expression of miR-378. All these features can be used as robust markers for quality control of VD3-treated regulatory DCs in future clinical studies.
由于缺乏一种广泛认可的生成人类调节性树突状细胞(DCs)的方法,尤其是不存在可靠的标志物,树突状细胞在诱导抗原特异性免疫耐受方面的临床应用受到了阻碍。因此,我们着手寻找能够通过简单方法检测的可靠标志物,以识别适用于未来临床研究的调节性DCs。人类DCs由外周血单核细胞在1α,25 - 二羟基维生素D(3)(VD3)存在的情况下生成,其产生的表型类似于未成熟DCs,但细胞表面高表达CD14且CD1a表达降低。这些经VD3处理的DCs对T细胞的刺激作用持久但效率低下,并诱导具有调节潜能的T细胞低反应性。重要的是,经VD3处理的DCs在暴露于成熟刺激时,通过低水平的白细胞介素-23分泌和miR-155的低表达,很容易与未处理的DCs区分开来。此外,经VD3处理的DCs显示出miR-378的过表达。所有这些特征都可作为未来临床研究中经VD3处理的调节性DCs质量控制的可靠标志物。